Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (291-300 of 499) with videos related to

Pageof 50
Sort By:
Journal of Geriatric Oncology|July 30, 2016
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT databaseDemetris Papamichael, Lindsay A Renfro, Christiana Matthaiou, et al.
ESMO Open|December 8, 2017
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trialEric Van Cutsem, Alfredo Falcone, Rocio Garcia-Carbonero, et al.
The Oncologist|February 22, 2023
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal CancerJosep Tabernero, Eric Van Cutsem, Elena Garralda, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 5, 2026
Young onset rectal cancer (YORC): a descriptive tertiary center analysisCédric Schraepen, Gertjan Rasschaert, Pieter Maerten, et al.
Journal of the National Cancer Institute|April 5, 2017
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II TrialTheo Ruers, Frits Van Coevorden, Cornelis J A Punt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2024
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic CancerEric Van Cutsem, Joelle Collignon, Rikke L Eefsen, et al.
Therapeutic Advances in Medical Oncology|November 20, 2024
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumorsPascal Hammel, Denis Smith, Pauline Afchain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapyAlain Hendlisz, Marc Van den Eynde, Marc Peeters, et al.
The Oncologist|December 4, 2020
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric CancerStefano Cascinu, György Bodoky, Kei Muro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2025
<i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 TrialZhihao Lu, Wenting Du, Xi Jiao, et al.
Pageof 50

Showing results (291-300 of 499) with videos related to

Sort By:
Pageof 50
Journal of Geriatric Oncology|July 30, 2016
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT databaseDemetris Papamichael, Lindsay A Renfro, Christiana Matthaiou, et al.
ESMO Open|December 8, 2017
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trialEric Van Cutsem, Alfredo Falcone, Rocio Garcia-Carbonero, et al.
The Oncologist|February 22, 2023
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal CancerJosep Tabernero, Eric Van Cutsem, Elena Garralda, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 5, 2026
Young onset rectal cancer (YORC): a descriptive tertiary center analysisCédric Schraepen, Gertjan Rasschaert, Pieter Maerten, et al.
Journal of the National Cancer Institute|April 5, 2017
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II TrialTheo Ruers, Frits Van Coevorden, Cornelis J A Punt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2024
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic CancerEric Van Cutsem, Joelle Collignon, Rikke L Eefsen, et al.
Therapeutic Advances in Medical Oncology|November 20, 2024
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumorsPascal Hammel, Denis Smith, Pauline Afchain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapyAlain Hendlisz, Marc Van den Eynde, Marc Peeters, et al.
The Oncologist|December 4, 2020
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric CancerStefano Cascinu, György Bodoky, Kei Muro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2025
<i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 TrialZhihao Lu, Wenting Du, Xi Jiao, et al.
Pageof 50